Orgenesis Interest Expense 2011-2026 | ORGS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Orgenesis

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-4.51 M	-2.5 M	-1.97 M	-1.29 M	-1.06 M	843 K	-3.12 M	-2.45 M	-1.26 M	1.85 M	-927 K	-78.7 K	-9.58 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.85 M	-4.51 M	-1.27 M

Quarterly Interest Expense Orgenesis

2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-718 K	-815 K	-852 K	-	-545 K	-692 K	-681 K	-	-1.1 M	-389 K	-213 K	-	-545 K	-406 K	-233 K	-	238 K	337 K	329 K	-	446 K	47 K	101 K	-	-1.07 M	587 K	-27 K	-	45 K	-503 K	-2.08 M	-	-574 K	-553 K	1.77 M	-	336	924	44	-	-2.21 M	-231 K	408 K	-	225 K	-264 K	-9.44 K	-	13.8 K	10	-99	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.77 M	-2.21 M	-260 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.35	0.68 %	$ 3.7 B	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
BioNTech SE BNTX	14.2 M	$ 103.69	2.08 %	$ 27.2 B	Germany
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Innate Pharma S.A. IPHA	440 K	$ 1.48	-0.67 %	$ 235 M	France
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.65	22.48 %	$ 6.01 M	Israel
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.08	0.74 %	$ 436 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 22.65	1.25 %	$ 2.88 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.42	0.71 %	$ 378 M	Britain
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Exelixis EXEL	-198 K	$ 45.0	0.69 %	$ 12.2 B	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands